Treatment Interruption after Pregnancy: Effects on Disease Progression and Laboratory Findings
Table 3
Median postpartum laboratory values among women continuing or stopping antiretroviral therapy postpartum according to therapy during pregnancy.
All women
ZDV monotherapy
Combination therapy
Parameter
+/-
+/+
P
+/-
+/+
p
+/-
+/+
P
CD4+ lymphocyte count
733.2
701.7
.47
725.2
711.0
.84
754
690.5
.33
CD4+ lymphocyte %
34.8
33.9
.42
34.2
32.6
.31
36.3
34.9
.44
CD8+ lymphocyte count
935.1
949.9
.81
985.3
1042.8
.56
818.4
874.0
.48
CD8+ lymphocyte %
44.7
44.7
.98
46.4
48.1
.41
40.8
41.9
.67
CD19+ %
9.0
9.6
.72
9.6
8.9
.72
CD8+CD57+ %
17.3
16.6
.80
18.8
18.8
.99
CD8+DR+ %
36.3
26.6
.02
35.9
24.9
.01
CD16+CD56+ %
4.8
7.4
.04
5.2
7.8
.12
CD8+CD38+ %
47.6
36.7
.001
49.8
40.5
.04
High sensitivity C-reactive protein (mg/L)
2.8
3.0
.69
2.7
3.1
.58
Cholesterol (mg/dL)
177.7
188.7
.10
177.7
188.7
.11
High density lipoprotein (mg/dL)
47.8
49.3
.56
48.1
49.2
.67
Low density lipoprotein (mg/dL)
95.6
101.5
.30
94.6
100.5
.35
Triglycerides (mg/dL)
180.0
184.7
.81
181.0
187.1
.77
Leptin (ng/dL)
21.0
19.3
.54
20.1
19.7
.90
Interleukin-6 (pg/dL)
1.9
1.6
.22
2.2
1.7
.33
1.7
1.6
.65
Lipoprotein phospholipase A-2 (ng/dL)
166.1
187.0
.05
170.6
188.5
.37
161.3
185.5
.05
+/- indicates women who stopped therapy at delivery; +/+ indicates women who continued therapy after delivery. Postpartum specimens were collected at six to 12 months postpartum.
